Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes and coronary revascularization.

James D Flaherty1, Charles J Davidson

  • 1Northwestern Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, Ill, USA.

JAMA
|March 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Adverse Events on Costs and Length of Stay Following Transcatheter Tricuspid Valve Replacement.

Structural heart : the journal of the Heart Team·2026
Same author

Left and Right Heart Remodelling at 1 Year After Transcatheter Versus Surgical Aortic Valve Replacement: A Speckle-Tracking Echocardiography Study.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same author

Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.

Circulation. Cardiovascular interventions·2026
Same author

Impact of Residual Mitral Regurgitation and Gradient After M‑TEER: 1‑Year Outcomes From the CLASP IID Trial.

JACC. Cardiovascular imaging·2026
Same author

Transcatheter Annuloplasty Using the Cardioband System: Insights From a European Multicenter Registry (TITAN Registry).

JACC. Cardiovascular interventions·2026
Same author

One-Year Outcomes of Screen Failures for Transcatheter Tricuspid Valve Repair: Insights From the TriSelect Study.

Circulation. Cardiovascular interventions·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

Diabetic patients undergoing coronary revascularization have worse outcomes. While coronary artery bypass graft (CABG) surgery shows mortality benefits over balloon angioplasty, newer stent technologies may alter these findings for percutaneous coronary intervention (PCI).

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Diabetology

Background:

  • Diabetic patients comprise 25% of coronary revascularization procedures in the US.
  • Diabetic patients experience poorer outcomes after revascularization compared to non-diabetic individuals.

Purpose of the Study:

  • To compare the effectiveness and safety of coronary artery bypass graft (CABG) surgery versus percutaneous coronary intervention (PCI) in diabetic patients.
  • To examine advancements impacting future outcomes for diabetic patients undergoing revascularization.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) comparing CABG and PCI in diabetic patients (1985-2004).
  • Inclusion of studies on drug-eluting stents (DES) versus bare-metal stents (BMS).
  • Literature review to identify clinical factors influencing revascularization outcomes in diabetes.

Related Experiment Videos

Main Results:

  • Six RCTs involving 950 diabetic patients were identified.
  • CABG demonstrated a mortality benefit over balloon-only PCI for multivessel disease, but not clearly against stent-assisted PCI.
  • PCI in diabetics showed higher repeat revascularization rates due to restenosis, significantly reduced by DES.
  • Glycoprotein IIb/IIIa inhibitors improved PCI survival in diabetic patients.

Conclusions:

  • Limited RCT data exists for current CABG vs. PCI practices in diabetic patients.
  • The historical mortality advantage of CABG may be diminished by advancements like DES and improved medical therapies.
  • Ongoing trials with DES are crucial to clarify outcomes in diabetic patients undergoing revascularization.